Recruiting

NCT Number: NCT06610669

The Prevalence of Hyper-Lp(a)-Emia in the PMMHRI-Lp(a) Registry

The PMMHRI-Lp(a)-Registry is a non-interventional, single-center registry conducted in the Polish Mother's Memorial Hospital Research Institute (PMMHRI). The PMMHRI-Lp(a)-Registry was established in January 2022. Since then, all consecutive patients of the Department of Cardiology and Adult Congenital Heart Diseases, Department of Endocrinology, and outpatient cardiology and endocrinology clinics with the measured Lp(a) concentration have been included.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lipoprotein(a), Hyper-Lp(a)-Emia

Sex eligibility

All sexes

Study type

Observational

Primary location

Polish Mother Memorial Research Institute

Lodz, 93-338, Poland

Location status: Recruiting

Location contact

Maciej Banach, MD,PhD,FNLA,FAHA,FESC,FASA

CONTACT

[email protected]

About this study

The PMMHRI-Lp(a)-Registry is a non-interventional, single-center registry conducted in Poland's 2nd largest, supra-regional hospital - the Polish Mother's Memorial Hospital Research Institute (PMMHRI). The PMMHRI-Lp(a)-Registry was established in January 2022. Since then, all consecutive patients of the Departments of Cardiology, Endocrinology, and outpatient cardiology and endocrinology clinics have been included. The indications for Lp(a) measurement in the registry are based on the 2021 Polish Lipid Guidelines and new Polish recommendations on the management of elevated Lp(a) (2024). Lp(a) was determined using Sentinel's Lp(a) Ultra, an Immunoturbidimetric quantitative test (Sentinel, Milan, Italy), and the results are presented in mg/dl.

The following information was collected from the patient's medical records: demographic parameters; relevant comorbidities; concomitant medications including lipid-lowering therapy status, anticoagulation status; smoking status; post hoc calculated cardiovascular risk score; and laboratory parameters including i.e. Lp(a) and lipids profile.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

measured lipoprotein(a) concentration

Exclusion criteria

Treatment and study plan

Primary outcomes

Prevalence of hyper-Lp(a)-aemia among the Polish population, along with the identification of associated patient characteristics and risk factors

Time frame: 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

Maciej Banach, MD,PhD,FNLA,FAHA,FESC,FASA

CONTACT

[email protected]

+48 42 2711599

Sponsors and collaborators

Lead sponsor

Polish Mother Memorial Hospital Research Institute

Other

Registry information

Official study title

The Prevalence, Patients' Characteristics, and Hyper-Lp(a)-Emia Risk Factors in the Polish Population. The Polish Mother's Memorial Hospital Research Institute Lipoprotein(a) Registry

Important dates

Study start: 2022
Primary completion: 2028
Study completion: 2028
First posted: Sep 24, 2024
Registry last updated: Sep 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Enrolling by Invitation

Implementation Research on the LILAC Method to Educate Management of Elevated Lipoprotein(a).

NCT07177612

Lipoprotein(a), Lipoprotein(a), Hyper-Lp(a)-Emia

Perth, Australia

View Trial Details